Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ZIPN 0.0015- 0.0016 MONSTER BOTTOM REVERSAL
In ZIPN 0.0007- 0.0008 selling done!! REVERSAL PLAY NOW
In ZIPN 0.0007- 0.0008 selling done!! REVERSAL PLAY NOW
TDGI 0.0150- 0.0180 :)
SYMW 0.0029- 0.0030
SYMW 0.0029- 0.0030
OMG TDGI 0.0140- 0.0150 now :0)
SYMW 0.0021 - 0.0022
TDGI 0.01 - 0.0120
TDGI 0.01 - 0.0120
SYMW 0.0018- 0.0019
TDGI Play could go wild jmo!
TDGI 0.01 print
TDGI 0.0080- 0.01 Monster gap :)
TDGI 0.0060- 0.01 Monster gap
TDGI could go 0.02+ today!!Possible R/M >>>
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39151908
TDGI 0.0060 - 0.01 Awesome alert
WOW TDGI gapping 0.0050- 0.01
SYMW 0.0017 on news
TDGI CHART:
TDGI CHART:
TDGI 0.0050-0.0055 possible R/M !
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39151908
TDGI 0.0050- 0.0055 was up 243.75 % possible R/M !
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39151908
VICL 2.81 going on news
SYMW 0.0015 SymPowerco Signs LOI to Acquire Majority Stake in Highline Hydrogen Hybrids
Tuesday, June 30 2009 7:30 AM, EST Market Wire "US Press Releases "
GARDNERVILLE, NV -- (MARKET WIRE) -- 06/30/09 -- SymPowerco Corporation (PINKSHEETS: SYMW) CEO John Davenport announced today that the company has signed a Letter of Intent ("LOI") with Texas businessman Steven Humphries for the acquisition of a majority interest in Highline Hydrogen Hybrids, Inc. ("HHHI"), the manufacturer of a unique and proven hydrogen conversion system for gasoline and diesel-powered vehicles.
In April of 2009, Humphries entered an agreement to purchase 70% of HHHI. Under the terms anticipated by today's Letter of Intent, Mr. Humphries will assign his HHHI interest to SymPowerco .
HHHI's unique supplemental hydrogen fuel system, in addition to reducing dangerous emissions, has been shown to enhance the fuel efficiency of internal combustion engines by as much as 25% and to increase horsepower by an average of 10%. HHHI also plans to release a commercial version of its supplemental fuel system for use on Over-The-Road commercial vehicles.
HHHI's unique hydrogen converter has undergone rigorous testing and has a patent pending. The company is currently relocating from Northwest Arkansas to a 380,000 square foot building on 30 acres in Dumas, Arkansas . HHHI officials project gross sales of their products to reach nearly $3,400,000.00 over the next 18 months.
Stated SymPowerco CEO John N. Davenport , "We at SymPowerco are very excited about the potential HHHI revenue streams and the synergies that HHHI's efficiency enhancing products could bring to our company. We believe that HHHI's products would complement our Flowing Electrolyte Direct Methanol Fuel Cell technologies by allowing SymPowerco to not only replace the internal combustion engine with the fuel cell in many applications but to also offer products to help reduce the environmental and energy-related impacts of the remaining fleet of vehicles powered by internal combustion engines."
SymPowerco Corporation href="http://us.lrd.yahoo.com/_ylt=AgpEG4tu3t0iUhx9Swj6pIeliRkC/SIG=1135gbi43/**http%3A/www.sympowercocorp.com/">develops advanced fuel cell and href="http://us.lrd.yahoo.com/_ylt=AhXuK2o565yQnrx0bjNYvXeliRkC/SIG=1135gbi43/**http%3A/www.sympowercocorp.com/">power delivery systems for the rapidly growing personal transportation and href="http://www.sympowercocorp.com/">portable power system markets being created by today's energy and environmental challenges.
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
Contact: Investor Relations 775-636-8486 Email Contact
VICL 2.20 Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response
Tuesday, June 30 2009 6:30 AM, EST GlobeNewswire "GlobeNewswire "
SAN DIEGO , June 30, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In addition, at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. The company is ready to advance directly to large-scale cGMP manufacturing of the vaccine for human clinical trials, subject to securing external funding for this program.
"Our DNA vaccine technology offers an innovative approach to dealing with pandemics," said Vijay B. Samant , President and Chief Executive Officer of Vical . "The speed of our platform both in development and manufacturing was demonstrated by our rapid completion of vaccine production and successful immunogenicity testing in animals while conventional vaccine manufacturers are still working toward production of their initial supply of H1 vaccine. We are encouraged by these compelling data with our Vaxfectin(r)-formulated DNA vaccine and we look forward to advancing to human clinical trials as soon as possible."
Vical's plasmid DNA vaccine contained the H1 hemagglutinin gene sequence provided by the U.S. Centers for Disease Control and Prevention (CDC) for the A/H1N1 influenza strain selected on April 30 . The preclinical vaccine was produced by May 11 and animal testing began on May 15 . In two parallel animal studies, one in mice and one in rabbits, vaccine was administered on Day 0 and Day 21, a standard regimen for pandemic influenza vaccines. Sera collected on Day 21, after a single dose of vaccine, showed clear increases over baseline hemagglutination inhibition (HI) titers in 100% of the animals, and HI titers above the protection threshold in 88% of the mice and 75% of the rabbits. Sera collected on Day 35, two weeks after the second dose, showed HI titers well above the protection threshold in 100% of the animals, ranging from 320 to 2,560 (geometric mean titer = 987) in the mice, and from 640 to 2,560 (geometric mean titer = 1,522) in the rabbits. The HI assay measures a vaccine's ability to prevent viruses from binding to cells, and HI titers of 40 or more are accepted as the threshold for potential protection against influenza viruses. The vaccine encoded H1 hemagglutinin from the swine-origin A/ California /04/09 wild-type influenza virus. Vical ran the HI assay against the swine-origin A/ California /07/09 x-179a reassortant influenza virus obtained from the CDC.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
The Vical Incorporated logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5768
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about Vical's vaccine technologies and their potential application in a vaccine against H1N1 influenza, potential human clinical testing of such a vaccine, as well as the company's focus, collaborative partners, and product candidates. Risks and uncertainties include whether external funding will be secured to support H1 DNA vaccine development; whether such vaccine will advance to clinical testing; whether results in animals will be predictive of results in humans; whether Vical or others will continue development of any influenza DNA vaccine candidates; whether H1N1 or any other strains of influenza will cause a pandemic; whether HI titers will be predictive of protection against H1N1 influenza; whether the company's DNA vaccine candidate will be effective in protecting humans against H1N1 or any other strains of influenza; whether any product candidates will be shown to be safe and effective; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission . These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACT: Vical Incorporated Alan R. Engbring (858) 646-1127 www.vical.com
Very nice finsh indeed,Tomorrow we should see 0.01+ !!!gltya
TDGI Sweet chart:
This one might go over 0.01+ today!!!RSI in power zone.
TDGI Sweet chart:
This one might go over 0.01+ today!!!
MOMO this one might go over 0.01+ today!!!
TDGI bid/ask u/t 0.0050- 0.0055 UP 212%.
TDGI bid/ask u/t 0.0050- 0.0055 UP 212%.
TDGI 0.0045- 0.0050 Monster!
Thanks for the charts 'TecNasty' Looking good buuddy :)
TDGI 0.0045- 0.0050 Monster!
TDGI 0.0036- 0.0045 falling here
TDGI 0.0035 - 0.0038
TDGI 0.0030- 0.0035 UP 137%
TDGI L 2 very thin ,could see 0.01!!!
TDGI 0.0030- 0.0040 now